Skip to main content

Table 4 Summary of treatment outcome

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Parameter Treatment Set
N = 88
PFS
 Patients who progressed or died, n (%) 70 (80)
 Median, months [95% CI] 17.0 [12.9–23.3]
Tumor response, n (%)
 Best overall response
  Complete response 2 (2)
  Partial response 69 (78)
  Stable disease 12 (14)
  Progressive disease 2 (2)
  Not evaluable 3 (3)
 ORR, n (%) [95% CI] 71 (80.7) [70.9–88.3]
Disease control
 DCR, n (%) [95% CI] 83 (94.3) [87.2–98.1]
 Duration of disease control, months [95% CI] 18.3 [13.6–23.7]
  1. CI confidence interval, DCR disease control rate, ORR objective response rate, PFS progression-free survival